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Abstract
We present a generative model, Lux, to quantify DNA methylation modifications from any combination of bisulfite
sequencing approaches, including reduced, oxidative, TET-assisted, chemical-modification assisted, and methylase-
assisted bisulfite sequencing data. Lux models all cytosine modifications (C, 5mC, 5hmC, 5fC, and 5caC) simultaneously
together with experimental parameters, including bisulfite conversion and oxidation efficiencies, as well as various
chemical labeling and protection steps. We show that Lux improves the quantification and comparison of cytosine
modification levels and that Lux can process any oxidized methylcytosine sequencing data sets to quantify all cytosine
modifications. Analysis of targeted data from Tet2-knockdown embryonic stem cells and T cells during development
demonstrates DNA modification quantification at unprecedented detail, quantifies active demethylation pathways and
reveals 5hmC localization in putative regulatory regions.
Keywords: DNA methylation, Bayesian analysis, Hierarchical modeling, TET proteins, 5-methylcytosine oxidation,
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Background
Many biological processes, including X-chromosome in-
activation [1], gene imprinting [2] and genomic instabil-
ity [3] are controlled by cytosine methylation, the most
widely studied epigenetic modification of DNA [4]. In
mammals, the bulk of DNA methylation in somatic cells
occurs as 5-methylcytosine (5mC), typically in a CpG se-
quence context. DNA methylation is dynamically altered
during normal development and abnormal changes have
been described in disease [5]. For instance, DNA methy-
lation is thought to contribute to cancer development by
diminishing genome stability and suppressing the ex-
pression of tumor-suppressor genes [6]. Comparison of
different cell types, including human embryonic stem
cells and fetal fibroblasts [7], has revealed differential
methylation at tissue-specific enhancers in various
mouse [8] and human [9] tissues, linking methylation to
cell development and differentiation [7–9]. DNA methy-
lation has also been mechanistically linked to splicing
regulation through inhibition of CTCF binding [10].
DNA methylation is also generally believed to have a re-
pressive effect at regulatory regions, although transcrip-
tional regulators can also selectively bind methylated
and unmethylated DNA [11]. Finally, DNA methylation
has been observed to accumulate during mammalian
brain development [12] and decrease during aging [13].
For all these reasons, it is important to quantify 5mC
changes accurately during embryonic development, cell
differentiation and oncogenesis.
Proteins of the TET (Ten-eleven translocation) family
were shown to be dioxygenases that converted 5mC to
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC)
and 5-carboxylcytosine (5caC) [14, 15]. These oxidized
methylcytosine (oxi-mC) species have multiple functions
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as intermediates in DNA demethylation (5mC→ C) as
well as stable epigenetic marks that recruit chromatin
regulators and interact with RNA polymerase [16–20].
However, the discovery that oxi-mC modifications
occur naturally in mammalian DNA has complicated
the analysis of DNA methylation. Initially, affinity-
based methods were used to map the location of 5mC
and 5hmC in genomic DNA, including immunoprecipi-
tation of methylated and hydroxymethylated DNA
using antibodies to 5-methylcytosine (MeDIP), 5-
hydroxymethylcytosine (hMeDIP), or cytosine 5-
methylenesulfonate (CMS, the adduct formed by
reaction of sodium bisulfite with 5hmC [21–23]), or
biotinylation of 5hmC using sodium periodate (GLIB) [24]
or click chemistry [25]. However, there are many obvious
advantages to mapping 5mC and oxi-mC at single base
resolution. First, compared with affinity-based methods,
which show a strong density bias [26], single-base reso-
lution methods are more sensitive at detecting 5hmC in
regions of low density CpGs. Second, if performed at
high sequence coverage, single-base resolution methods
are more sensitive at detecting minor and dynamic
changes of oxi-mC, which are likely to be important in
many different biological processes. Third, single-base
resolution methods can detect localized dynamic
changes of oxi-mC, such as oscillating distribution of
5hmC around CTCF binding sites and its correlation
with nucleosome positioning [27, 28]. Fourth, single-
base resolution methods can detect strand-specific
modifications that might be associated with transcrip-
tional activity.
For many years, the most widely used method for
quantification of DNA methylation at a single-base level
was bisulfite sequencing (BS-seq), the gold standard for
methylation profiling [7–9, 12, 29]. Unlike affinity-based
approaches, BS-seq provides methylation information at
the single-nucleotide resolution by introducing single
nucleotide changes into DNA sequence in a methylation-
dependent manner [30]. Briefly, treatment of genomic
DNA with sodium bisulfite results in rapid deamination of
unmodified cytosine to uracil, which is read as thymine
after PCR amplification and sequencing (C→T conver-
sion). In contrast, 5mC is deaminated much more slowly,
and so remains unconverted and is read as C. Unfortu-
nately, bisulfite sequencing has proved inadequate to detect
oxi-mCs: 5hmC reacts with sodium bisulfite to form a new
adduct, cytosine 5-methylenesulfonate [21], that is resistant
to deamination like 5mC, whereas 5fC and 5caC are prone
to deamination like unmodified C. Thus, bisulfite sequen-
cing cannot distinguish 5mC and 5hmC, which are both
read as C after PCR amplification, nor can it distinguish un-
modified C from 5fC or 5caC, which are all read as T [31].
The previously reported contradictory functions of
5mC in gene regulation [7] are partly due to the inability
of BS-seq to distinguish 5hmC from 5mC. To overcome
the limitations of BS-seq, oxBS-seq (oxidative bisulfite
sequencing) [32] and TAB-seq (Tet-assisted bisulfite
sequencing) [28] have been developed to differentiate
5hmC from 5mC at a single nucleotide level. Both tech-
niques use oxidation; KRuO4 oxidizes 5hmC to 5fC in
oxBS-seq [32], whereas in TAB-seq, 5hmC is protected
by β-glucosyltransferase and recombinant mouse Tet1 is
used to oxidize 5mC to 5caC [28]. Importantly, oxBS-seq
and TAB-seq have to be combined with BS-seq in order to
distinguish C, 5mc and 5hmC and to quantify their levels.
Recently, several new sequencing protocols have been
developed to quantify further oxidized methylcytosines
in DNA (reviewed in [33]). In fCAB-seq (5fC chemical
modification-assisted bisulfite sequencing) [34], O-ethylhy-
droxylamine (Et-ONH2) modifies 5fC and protects it from
deamination by sodium bisulfite, whereas NaBH4 reduces
5fC to 5hmC in redBS-seq (reduced bisulfite sequencing)
[35]. Subsequent sequencing of modified or reduced 5fC in
fCAB-seq and redBS-seq, respectively, reads 5fC similarly
with 5mC and 5hmC. Thus, quantification of 5fC becomes
possible when fCAB-seq or redBS-seq data are combined
with the standard BS-seq data obtained from the same
sample. Similarly with fCAB-seq, in CAB-seq (chemical
modification-assisted bisulfite sequencing) [36] 1-ethyl-3-
[3-dimethylaminopropyl]-carbodiimide hydrochloride (EDC)
selectively protects 5caC from deamination during bisul-
fite treatment and quantification of 5caC requires CAB-
seq to be combined with BS-seq data. In MAB-seq (M.SssI
methylase-assisted bisulfite sequencing) [37], unmethy-
lated C is methylated with the bacterial DNA CpG meth-
yltransferase M.SssI. Sequencing of the M.Sssl and sodium
bisulfite treated DNA then discriminates 5fC and 5caC
from other DNA methylation modifications. All afore-
mentioned methods are challenging and sensitive to vari-
ation in various experimental steps, often resulting in
sample-specific biases. Moreover, although TAB-seq or
oxBS-seq selectively detect 5hmC and 5mC, respectively,
in all other methods several modifications are convoluted
and, thus, the underlying true modification levels, or pro-
portions, need to be computationally inferred from a com-
bination of these data sets.
Various computational methods exist for analyzing
BS-seq data from Sanger and high-throughput sequen-
cing — for instance, QUMA [38], BISMA [39],
methylKit [40], GBSA [41], BSmooth [42], MOABS [43],
a Bayesian hierarchical model [44], MethylSeekR [45],
and RadMeth [46]. These methods provide means to
quantify levels of methylation, visualize data and detect
differential methylation. Depending on the biological
question, the quantification of methylation is done either
at individual cytosines, in sliding window fashion or
for predefined genomic regions, such as promoters,
CpG islands or shores. Earlier methods (e.g., QUMA,
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methylKit) make no specific statistical assumptions
about data characteristics, whereas BSmooth models
the distribution of converted and unconverted cytosine
counts with binomial distribution, which was extended
to a hierarchical beta-binomial model in MOABS and
other methods [43–46] to account for biological vari-
ation. Different measures have been proposed for call-
ing differential methylation — for instance, Fisher’s
exact test [7] on the counts of converted and uncon-
verted cytosines, Mann–Whitney U-test [38] or a
modified t-test [42] on methylation profiles, and the
credible methylation difference metric calculated be-
tween methylation level distributions [43]. Although
these methods are applicable for analyzing BS-seq/
oxBS-seq data separately, they lack support for integra-
tive analysis of different methylation states (the per-
centages of which need to add up to 100 %) from BS-
seq and oxBS-seq data. Consequently, the previously
proposed methods use a naïve integration, such as sub-
traction, of the individual methylation state estimates,
which is prone to erroneous estimates. Recently, the
MLML method was published, which provides consist-
ent methylation (non-negative and adds up to 100 %)
estimates from BS-seq, oxBS-seq, and TAB-seq data
using the expectation maximization algorithm [47].
However, no method exists to analyze other oxi-mC-
seq data (other than simple subtraction of read counts)
and, importantly, previous methods do not take into
account experiment-specific variation in the biochem-
istry. These non-ideal experimental parameters in-
clude, e.g., bisulfite conversion, oxidation efficiencies,
chemical labeling and protection steps and sequencing
errors, and their experimental significance has been
demonstrated [28, 32, 34, 37]. Notable exceptions in-
clude the computational methods introduced in [12,
28, 32] which use the binomial test together with a
conversion inefficiency parameter to quantify the sig-
nificance (i.e., p value) of 5mC > 0 and 5hmC > 0. How-
ever, the use of these early methods is limited as they
provide neither a way to accurately quantify cytosine
modification levels nor a method to assess differential
methylation.
To study active demethylation and to characterize un-
known functions of oxi-mC species, a rigorous statistical
analysis of BS-seq and oxi-mC-seq data is needed for ac-
curate quantification of different cytosine modifications
and detection of differential methylation between condi-
tions. To fill this gap we present an integrative hierarch-
ical model, Lux, which is inspired by the aforementioned
measurement processes. This probabilistic generative
model enables accurate and unbiased quantification of
different cytosine modifications and differential methy-
lation at individual cytosines or loci, with or without
replicates, while taking imperfect and sample-specific
experimental parameters into account. Full Bayesian in-
ference quantifies the effect of the uncertainties in data
and parameters to the final estimates. Lux is applicable
for analyzing any number and combination of BS-seq
and oxi-mC-seq data sets from whole genome, reduced
representation or targeted experiments, and provides
the most accurate methylome estimates when samples
are spiked-in with stretches of unmethylated and meth-
ylated (5mC, 5hmC, 5fC, and/or 5caC) control DNAs.
These features were benchmarked extensively on real
and simulated data, including BS-seq, oxBS-seq, TAB-
seq, and fCAB-seq. We also show that the statistical
framework is easily extended for other existing data
types, such as CAB-seq, redBS-seq, and MAB-seq, as
well as upcoming derivatives of traditional bisulfite se-
quencing. A platform-independent implementation of
Lux is released under MIT license at https://github.-
com/tare/Lux/ and as Additional files 1 and 2.
Results and discussion
Method overview
We first describe how Lux can be applied to simultan-
eously analyze C (together with 5fC and 5caC), 5mC and
5hmC from BS-seq and oxBS-seq data, and later extend
Lux to other data types. BS-seq and oxBS-seq provide
partially orthogonal, but convoluted, information on
methylation status (Fig. 1a) as BS-seq reads discriminate
5mC and 5hmC from C whereas oxBS-seq reads dis-
criminate 5mC from C and 5hmC. Thus, together they
provide the data required for quantifying levels of C,
5mC and 5hmC. Two straightforward approaches for
quantifying 5hmC levels from BS-seq and oxBS-seq data
calculate the difference in proportions of unconverted
cytosines [32] or the difference of separately estimated
proportions [43], respectively, resulting in unconstrained
maximum likelihood estimates (termed as frequency
method; see Additional file 3). Unfortunately, both ap-
proaches can lead to erroneous estimates, such as nega-
tive values for 5hmC, because the cytosine modification
levels are tightly interconnected. Moreover, the read-
outs from BS-seq and oxBS-seq assays depend on the ef-
ficiencies of bisulfite conversion and oxidation (Fig. 1a).
We considered the following experimental parameters:
bisulfite conversion (BSeff ), inaccurate bisulfite conver-
sion (BS*eff; Figure S1a in Additional file 4), oxidation
(oxeff ) efficiencies and sequencing errors (seqerr). To
quantify the C, 5mC and 5hmC proportions from BS-
seq and oxBS-seq data while taking into account the ex-
perimental parameters; we formulated a probabilistic
generative model (see "Materials and methods"). First,
for each cytosine modification, we write the probabilities
of the BS-seq and oxBS-seq outcomes in the terms of
experimental parameters BSeff, BS*eff, oxeff and seqerr
(Fig. 1b, c; Figure S1b, c in Additional file 4). Next, we
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modeled cytosine-specific methylation states (C, 5mC
and 5hmC) with cytosine-specific probabilities θ = [p(C),
p(5mC), p(5hmC)] (Σθ = 1) and weighted the probabil-
ities of the BS-seq and oxBS-seq outcomes with the pro-
portions in θ (Additional file 4: Figure S1d; see
"Materials and methods"). Consequently, the BS-seq and
oxBS-seq outcomes are Bernoulli distributed with the
aforementioned weighted and summed success probabil-
ities; moreover, the frequencies of the sequencing read-
outs are binomially distributed (Figure S2 in Additional
file 4). The capability of analyzing data from repeated
biological experiments in Lux is implemented by adding
a hierarchical level for modeling biological variation be-
tween the replicate-specific proportions θi from the
common proportions μ (Figure S2 in Additional file 4;
see "Materials and methods"). The statistical model is
described in more detail in "Materials and methods" and
in full detail in Additional file 3.
Bayesian inference of the model yields posterior distri-
butions of the model parameters conditioned on data
(see "Materials and methods"). This starts by specifying
prior distributions on the model parameters (Figure S2
in Additional file 4; Table S1 in Additional file 5; see
"Materials and methods"). The model inference was im-
plemented in Stan, which utilizes the Hamiltonian
MCMC strategy (HMC) with the No-U-turn sampler
(NUTS) for estimating posterior distributions with fast
convergence [48] (see "Materials and methods"). In prac-
tice, Lux with the model suitable for distributed comput-
ing (Figure S2b in Additional file 4) is able to analyze
approximately 15,000 cytosines for a single replicate in
an hour on a single core (Figure S2c in Additional file 4).
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Fig. 1 The effect of imperfect bisulfite conversion and oxidation efficiencies on BS-seq and oxBS-seq assays. a The read-outs for C, 5mC and
5hmC in BS-seq and oxBS-seq assays. The arrows indicate which read-outs are affected by bisulfite conversion and/or oxidation efficiencies. b The
bisulfite conversion of C followed by sequencing. The four possible scenarios of sequencing “C” or “T” are expressed in terms of BSeff and seqerr.
Oxidation does not have an effect on C so this model also applies to the oxBS-seq measurement of C. c The oxidation of 5hmC followed by
bisulfite treatment and sequencing. The eight possible scenarios of sequencing “C” or “T” are expressed, stated in terms of BSeff, BS*eff, oxeff and
seqerr. Under bisulfite treatment, without the preceding oxidation step, 5hmC and 5mC react in the same way. d The posterior mean methylation
proportions across the control loci in v6.5 (left panel) and Tet2kd (right panel) samples. The different replicates are in the columns. The bars show
the arithmetic means of the posterior means of the individual cytosines. The one-sided error bars (mean – standard deviation is depicted) show
the standard deviations. e Posterior distributions of oxidation efficiencies across biological conditions (v6.5 in top panel; Tet2kd in bottom panel)
and replicates. Kernel density estimates with the Gaussian kernel (the bandwidth obtained with Scott’s rule) are shown
Äijö et al. Genome Biology  (2016) 17:49 Page 4 of 22
Notice that run time requirement with respect to repli-
cates increases sub-linearly. Thus, as demonstrated in this
study by utilizing a computing cluster, one can analyze all
cytosines in a CpG context in mammalian genomes in
several hours, therefore rendering Lux applicable for inte-
grative analysis of oxi-mC data with or without replicates
in a genome-wide setting.
Estimation of experimental parameters
We focused on 14 previously studied genomic loci cov-
ering approximately 2000 cytosines in wild-type (v6.5)
and Tet2 knockdown (Tet2kd) v6.5 embryonic stem cells
[49] and carried out targeted BS and oxBS sequencing
with three biological replicates. Ten of the selected loci
were highly statistically significantly differentially meth-
ylated and had varying methylation states based on the
previous mapped 5hmC and 5mC methylomes [49] ob-
tained using CMS-IP (cytosine-5-methylenesulfonate
immunoprecipitation) and MeDIP (methylated DNA im-
munoprecipitation) antibody techniques. Four of the loci
showed no differential methylation [49]. The obtained
high coverage (median cytosine coverage 2042×) data
sets on the selected loci provided an ideal backdrop for
assessing the applicability of Lux, and for comparing
Lux’s accuracy with that of other methods. To estimate
the bisulfite conversion rates and oxidation efficiencies,
the sequencing libraries were spiked with stretches of
unmethylated, methylated and hydroxymethylated DNAs
(see "Materials and methods"). The Cs and 5mCs in the
control DNA are close to 100 % unmethylated and
methylated, respectively, while 5hmC has ~90 % purity,
reflecting the purity of the 5hmCTP obtained from the
manufacturer [28]. This prior knowledge was plugged
into the model through the prior distributions (Table S1
in Additional file 5; Figure S2a in Additional file 4; see
"Materials and methods"). Next the model was condi-
tioned on the data and the posterior distributions of the
methylation states of the control DNA (Fig. 1d) and ex-
perimental parameters (oxidation efficiencies shown in
Fig. 1e; others are listed in Table S2 in Additional file 5)
were derived (see "Materials and methods"). C and 5mC
controls were close to ideal, whereas 5hmC controls had
more experimental variation, presumably because of the
impure dhmCTP mix and experimental challenges
(Fig. 1d). The small standard deviations of the estimates
demonstrate the identifiability of the experimental pa-
rameters. The experimental variation in the parameters
(oxeff from 0.48 to 0.89) emphasizes the importance of
considering them while estimating methylation levels
and comparing methylation levels among samples
(Fig. 1e). In addition to impure dhmCTP mixes, the
amount of 5hmC in the genomic DNA might affect the
oxidation efficiency, and thus the higher oxidation effi-
ciency in Tet2kd cells might be due to the reduced
amount of 5hmC in Tet2kd cells compared with that in
v6.5 cells. Importantly, 5hmC estimates would be under-
estimated in the v6.5 samples if the sample-specific oxidiza-
tion efficiency was not taken into account, as implemented
in Lux. As expected, other parameters were close to ideal
(Table S2 in Additional file 5).
In addition, we carried out an in silico experiment to
enable a more controlled evaluation (Figure S3a in
Additional file 4). Briefly, we studied the identifiability
of the model by testing different settings of experimental
parameters, number of control cytosines, and coverage
levels. The simulation results also demonstrate a good
identifiability of the experimental parameters since they
can be estimated even from a single control cytosine
(Figure S3b in Additional file 4). Moreover, simulation
results suggest that with 20 control cytosines per
methylation modification, the experimental parameters
can be accurately estimated and their accuracy saturates
at 48× coverage (Figure S3c in Additional file 4).
Estimation of methylation levels
The methylation statuses of all the cytosines with at least
10× coverage across all six samples (N = 2428) were esti-
mated (Table S3 in Additional file 5) simultaneously with
the estimation of experimental parameters. As expected,
there was wide variation in the DNA methylation levels
of cytosines in a CpG context (left panel in Fig. 2a), but
no 5mC or 5hmC in cytosines located in a non-CpG
(CHG/CHH) context (right panel in Fig. 2a). Because
TET family proteins oxidize 5mC to 5hmC, 5fC and
5caC, a Tet2kd is expected to block this demethylation
pathway and increase the level of 5mC. Notably, 5mC
levels for 179 out of 384 cytosines were increased in
Tet2kd cells (pTet2kd(5mC) − pv6.5(5mC) > 0.1) (Fig. 2a).
These cytosines were also highly marked by 5hmC in
v6.5 cells (Fig. 2a), suggesting the expected scenario in
which Tet2 depletion resulted in loss of 5hmC and con-
comitantly increased 5mC. However, the demethylation
process is reduced rather than entirely blocked in Tet2
knock-down mESCs, either because of incomplete deple-
tion and residual TET2 activity or compensatory activity
of other TET enzymes, most likely TET1 [49]. More
generally, we observed an inverse correlation between
5mC and 5hmC levels (Figure S4 in Additional file 4)
reflecting the inherent relationships between cytosine
modifications in the active demethylation pathway.
To confirm Lux’s ability to estimate methylation levels,
we compared our estimates with published 5hmC and
5mC methylome maps [49] obtained using CMS-IP and
MeDIP antibody techniques, respectively. For example,
in a methylated locus (Runx1), Lux estimated qualita-
tively similar 5mC and 5hmC levels from BS- and oxBS-
seq data before and after Tet2 depletion (Fig. 2b, top).
However, detailed analysis of individual CpGs showed
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the expected loss of 5hmC and gain of 5mC in Tet2-de-
pleted relative to parental v6.5 embryonic stem cells
(Fig. 2c), confirming previous conclusions from compari-
sons of CMS-IP and MeDIP peaks (Fig. 2b, bottom)
[49]. Additionally, as a negative control, no 5mC or
5hmC were detected within the tested unmethylated loci
(Figure S5 in Additional file 4). Results on other loci are
similar (data not shown).
A recently published method, MLML, provides con-
sistent methylation estimates by calculating the con-
strained maximum likelihood estimates using the
expectation maximization algorithm [47]. To study the
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differences between Lux and MLML, we analyzed our
BS-seq and oxBS-seq data using MLML and then com-
pared the results with the ones obtained using Lux. First,
the obtained C and 5mC level estimates correlate well
between biological replicates for both of the two
methods (Figure S6a in Additional file 4), although 5mC
estimates from Lux correlate slightly better between bio-
logical replicates. Next we analyze all cytosines in a CpG
context using Lux and observe that 5hmC correlations
between replicates range from 0.45 to 0.52, which are a
bit low but still higher than those from the MLML
method (from 0.35 to 0.41) (Fig. 2d). MLML’s poor per-
formance is likely affected by several biological and
methodological factors, particularly the lack of experi-
mental parameters in the MLML model. While Lux in-
corporates experiment-specific experimental parameters
in estimating methylation modifications, these are not
included in the MLML model, which together with vari-
ation in the oxidation efficiencies (Fig. 1e) can explain
MLML’s lower 5hmC correlation values.
We further validated Lux’s performance on BS-seq
and oxBS-seq data from Booth et al. [35]. We analyzed
the BS-seq and oxBS-seq libraries (two biological repli-
cates) while assuming 1) ideal experimental parameters
(BSeff = 1, oxeff = 1, BS
*
eff = 0, seqerr = 0) or 2) non-ideal
experimental parameters (BSeff = 0.99, oxeff = 0.85, BS
*
eff =
0.001, seqerr = 0.001) (see "Materials and methods"). Then
we compared the resultant 5mC and 5hmC level esti-
mates to glucMS-qPCR measurements (measured using
a bisulfite-free and restriction enzyme-based assay) from
[35]. We carried out the same comparison for the BS-seq
and oxBS-seq analysis method from [35]. As expected,
the Lux estimates obtained with the ideal experimental
parameters have a slightly better correlation with the
glucMS-qPCR measurements than the Booth et al. esti-
mates (Table S4 in Additional file 5), particularly for
5hmC levels (0.54 versus 0.57). When the non-ideal ex-
perimental parameters are incorporated into the Lux
analysis, we observe more accurate quantification of
methylation levels (Table S4 in Additional file 5). Al-
though the correlation of 5mC levels remains practically
unchanged, the correlation of 5hmC levels increases
from 0.57 (p = 0.007) to 0.63 (p = 0.002). Moreover,
comparison of the correlation measures between Lux
and the method from Booth et al. [35] shows a marked
improvement for 5hmC quantification; correlation in-
creases from 0.54 (p = 0.012) to 0.63 (p = 0.002).
Additionally, we carried out an in silico experiment
simulating a replicate-free experiment to study the effect
of sequencing coverage on the Lux and MLML estimates
[47], thus providing guidelines for experiments (Figure S6b
in Additional file 4). In short, we compared the Lux and
MLML estimates of methylation levels using simulated
data from different methylation level/coverage settings
with controls. The results further demonstrate the import-
ance of both integrative analysis of all cytosine modifica-
tions simultaneously and accounting for the experimental
parameters in estimating C, 5mC and 5hmC levels be-
cause the MLML estimates are consistently biased, i.e., the
medians are deviated from the true values (Figure S6c in
Additional file 4). Notably, this holds for both hypo- and
hyper-5mC (methylation levels of p(C) = 0.8, p(5mC) =
0.1, and p(5hmC) = 0.1 and p(C) = 0.1, p(5mC) = 0.8,
and p(5hmC) = 0.1) and situations with high but realis-
tic 5hmC levels (p(5hmC) = 0.3), commonly observed
in various applications. Note in particular that ignoring
the experimental parameters results in consistent
underestimation of the already less abundant 5hmC
species levels. Lux also has a small bias for low sequencing
depths due to the prior distribution used in Bayesian ana-
lysis. Importantly, the more experimental data one has,
the smaller the bias in Lux estimates becomes, i.e., Lux
provides consistent methylation level estimates. The user
can also adjust the strength of the prior; a less informative
prior produces less bias, whereas a stronger prior pro-
duces less variance for low sequencing depth. In this
simulation experiment, approximately 48× coverage is
enough for Lux to produce accurate methylation propor-
tion estimates. Supposedly, a higher sequencing depth is
needed when the 5hmC level is lower and/or the experi-
mental parameters are impaired. We also simulated bio-
logical replicates to gain information on the effect of
replicates on methylation level estimates (Figure S7a, b in
Additional file 4). As expected, the accuracy of estimates
is commensurate with the number of replicates and more
replicates are needed as the divergence between the distri-
bution of interest and prior increases (Figure S7c–e in
Additional file 4). Overall, these results demonstrate that
Lux is able to infer biological variation from BS- and
oxBS-seq data, which is essential in detecting differential
methylation.
Detection of differential methylation
Next we describe how Lux identifies differential methyla-
tion between conditions A and B. Briefly, two hypotheses,
or models, are formulated (see "Materials and methods"):
the null hypothesis H0 where Δμ = μA − μB = 0 (no differ-
ential methylation); and the alternative hypothesis H1
where Δμ = μA − μB ≠ 0 (differential methylation). In a
Bayesian setting the data support for the hypothesis H1
over H0 can be quantified using the Bayes factor (BF; see
"Materials and methods"). Here the BFs are approximated
using the Savage-Dickey density ratio approach, which has
recently been used, e.g., in detecting alternative splicing by
Katz et al. [50]. The Savage-Dickey formulation involves
calculation of the ratio BF ≃ p(Δμ = 0|H1)/p(Δμ = 0|H1,D).
Succinctly, the term in the numerator is calculated from
the prior distributions of μ for which we derive a closed-
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form solution, and the denominator is calculated from
the posterior for which we use samples from the HMC
sampler (see "Materials and methods").
We compared Lux, MOABS, and FET for detecting
differential methylation on real data. We divided all the
covered cytosines in a CpG context (N = 384) into sets
of differentially (N = 252) and similarly (N = 132) methyl-
ated cytosines based on independent CMS-IP and MeDIP
loci-level information (see "Materials and methods"). Ob-
viously, CMS-IP and MeDIP do not give information on
methylation at a single-nucleotide resolution level; how-
ever, in many cases the methylation of nearby CpG sites is
highly correlated. Since we consider short loci, presumably
the obtained ground-truth sets are largely correct and, im-
portantly, obtained using a method independent of BS-seq
and oxBS-seq protocols. The use of FET and MOABS re-
quire that replicates are pooled and BS-seq and oxBS-seq
data are analyzed separately (see "Materials and methods").
To investigate the effect of coverage, we analyzed the data
using either the full data set or reduced data sets down-
sampled to either 12× or 30× coverage. The cytosines
were listed in descending order of evidence for differential
methylation (descending and ascending order of p values
and BFs, respectively), and the methods were compared
using the area under the curve (AUC) of receiver operat-
ing characteristic (ROC) curves (Fig. 3c; Figure S8c in
Additional file 4). Lux provided better performance
on the 12× down-sampled data with realistic cover-
age (AUC = 0.8743) than MOABS (AUCBS = 0.8197,
AUCoxBS = 0.8500) or FET (AUCBS = 0.6765, AUCoxBS =
0.7526). The results were highly similar on the 30× down-
sampled data (Lux AUC= 0.8748; MOABS AUCBS =
0.8197, AUCoxBS = 0.8500; and FET AUCBS = 0.6765,
AUCoxBS = 0.7526; Figure S8c in Additional file 4). As ex-
pected, the results of the methods on the full coverage
data set were close, but Lux still provided the best per-
formance; the AUC values were 0.8728 for Lux, AUCBS =
0.7446 and AUCoxBS = 0.7697 for FET, and AUCBS =
0.8678 and AUCoxBS = 0.8576 for MOABS. Additionally,
we tested the binomial test with conversion efficiency
method [32] on our data (see "Materials and methods").
The performance of the method was poorer than those
of Lux, MOABS, and FET, which is expected since the
method is primarily designed for the detection of
methylation (Figure S8d in Additional file 4). These re-
sults collectively show that the integrative analysis of
BS-seq/oxBS-seq data and the model-based analysis of
replicates by Lux result in improved performance on
data with realistic sequencing coverage.
From the ten differentially methylated and four non-
differentially methylated loci covered by our targeted
experiments, we identified that 30 individual cytosines,
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regardless of sequence context, were differentially meth-
ylated between v6.5 and Tet2kd cells (BF > 1, i.e., the
posterior probability of H1 exceeds that of H0, corre-
sponding to ‘weak evidence’). Eight of the cytosines had
at least ‘substantial evidence’ (BF > 3) for differential
methylation (Figure S9a in Additional file 4; Table S3 in
Additional file 5). For comparison, FET and MOABS are
very non-conservative, as FET detected 464 (BS-seq)
and 788 (oxBS-seq) and MOABS 226 (BS-seq) and 316
(oxBS-seq) differentially methylated cytosines (Benjamini-
Hochberg false discovery rate (FDR) < 0.01). Although Lux
is more conservative in reporting significant differential
methylation, nevertheless, ROC analysis confirms that Lux
is more accurate in discriminating differential methylation
from non-differential methylation (Fig. 3c; Figure S8c in
Additional file 4). The changes detected by Lux were
supported by antibody-based approaches (Figure S10 in
Additional file 4). Notably, the amount of evidence for
differential methylation decreases significantly when
ideal experimental parameters (i.e., BSeff = 1, BS*eff = 0,
oxeff = 1, and seqerr = 0) are used in the model (Figure
S9b in Additional file 4), thus further emphasizing the
importance of accounting for the experimental parame-
ters. The condition-specific posterior distributions of
the methylation levels for the top hits from the loci
chr4:139,783,236–139,784,235 and chr15:61,868,386–
61,869,385 show the expected pattern of TET2-dependent
demethylation, i.e., increased 5mC and decreased 5hmC
levels in Tet2kd samples (Fig. 3b; Figure S10a, c in
Additional file 4). Intriguingly, these loci reside in the
vicinity of a promoter of a long non-coding gene, Pvt1
(plasmacytoma variant translocation 1; Figure S10c in
Additional file 4) and an intronic enhancer within
Igsf21 (immunoglobin superfamily, member 21; Figure
S10a in Additional file 4) identified in mESCs [51]. Unex-
pectedly, the cytosine having the third highest BF,
chr15:100,300,108, shows unaffected 5mC (pv6.5(5mC) =
0.23/pTet2kd(5mC) = 0.20) but increased 5hmC upon Tet2
knock down (pv6.5(5hmC) = 0.02/pTet2kd(5hmC) = 0.34)
(Figure S10b in Additional file 4). Possibly, the down-
stream demethylation pathway (5hmC→C) is dependent
on TET2. In conclusion, detection of modest changes
caused by an individual enzyme (TET2) requires primarily
biological replicates but not exceedingly deep sequencing
per sample (Figure S8f in Additional file 4) and con-
sideration of experimental parameters (Figure S9b in
Additional file 4), whereas near complete methylation
(p(5mC) = 0.95) and unmethylation (p(C) = 0.95) can
be distinguished from each other without biological
replicates even with a low sequencing coverage (Figure
S8g in Additional file 4).
Additionally, to guide experimental design in future
studies, we applied Lux, Fisher’s exact test and MOABS
to in silico data with realistic genome-wide coverage
(12×) and varying number of replicates. First, as desired,
Lux does not detect differential methylation between
identical conditions and the detection sensitivity of dif-
ferential methylation increases together with the number
of replicates and the magnitude of differential methylation
(Figure S8a, b in Additional file 4). Second, consistent with
our results on real data, we observed that Lux (AUC=
0.9443) outperformed FET (AUCBS = 0.7919, AUCoxBS =
0.8706) and MOABS (AUCBS = 0.8001, AUCoxBS = 0.8806)
in discriminating differential methylation from nondiffer-
ential methylation (Fig. 3d). For the amount of biological
variation and differential methylation used in our simula-
tions, strong evidence (BF > 10) for differential methylation
is typically obtained with two or more replicates. Taken to-
gether with results from real data (Fig. 3; Figures S8f, g, S9
and S10 in Additional file 4) we expect that three bio-
logical replicates with only modest sequencing coverage
are sufficient to detect larger differential methylation
changes in controlled molecular biology studies. As methy-
lation modification level changes in disease studies can be
modest, our results support the use of larger sample sizes
even at the price of sequencing coverage.
To gain more statistical power for managing biological
variation one can move from the individual cytosine
level to the loci level [7]. In Lux, this is implemented by
assuming that the methylation levels of cytosines within
a locus follow the same μ distribution while allowing
variation between individual cytosines within a locus
(Figure S11a in Additional file 4; see "Materials and
methods"). We scanned the 14 loci with window-length
100 bp and 50 bp step size (Table S5 in Additional file 5;
see "Materials and methods"). Altogether, we identified
16 windows from six different loci having BF > 1; as ex-
pected, 14 out of these 16 windows exhibited increased
5mC and decreased 5hmC levels in Tet2kd compared
with v6.5 cells. As an example, this approach led to pos-
terior distributions on the locus chr15:61,868,740–
61,868,840 having great kurtosis (BF > 1e16; Fig. 4a) even
though the individual cytosines, of which only two have
BF > 1, are variably methylated across the locus and be-
tween biological replicates (Fig. 4b). In other words, the pro-
posed loci level analysis scheme achieves greater sensitivity
for detecting modest changes in methylation, which is an
anticipated feature of studies without biological replicates or
with large biological variability. Additionally, comparison of
these loci-level differential methylation analysis results with
the independent CMS-IP and MeDIP validation data shows
that Lux is more accurate in detecting differential methyla-
tion than MOABS (Figure S11b in Additional file 4).
DNA demethylation dynamics during mouse T-cell
development
To further demonstrate the applicability of Lux for analyz-
ing dynamic DNA methylation/demethylation changes
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during T-cell development, we measured DNA modifica-
tions for five loci in double positive (DP), CD4 single posi-
tive (SP) and naïve CD4 T cells using targeted BS and
oxBS sequencing. The five loci distributed in Il6ra, Prkcq,
Zbtb7b (two loci), and Pax5 were selected because they
are important for mouse T-cell development and 5hmC
levels were dynamically changed during mouse T-cell de-
velopment based on an antibody-based assay [52]. The
resulting methylome snapshots of three biological repli-
cates enabled us to study DNA methylation through three
consecutive developmental stages during mouse T-cell de-
velopment at single-base resolution.
The sequencing libraries were spiked with stretches of
unmethylated, methylated and hydroxymethylated DNAs
as described previously (see "Materials and methods").
Strikingly, when estimating the experimental parameters
as described above, each cytosine in the hydroxymethy-
lated control DNA was estimated to be lowly hydroxy-
methylated (p(5hmC) ≃ 0.1) contrary to our prior belief
of ~90 % purity of the 5hmCTP mix (Figure S12a in
Additional file 4; Table S6 in Additional file 5). To con-
firm the impurity of the 5hmCTP mix, we performed a
dotblot assay to quantify the 5hmC level in the new
spike-in 5hmC-containing oligonucleotides used in this
study (Figure S12b in Additional file 4). Indeed, the dot-
blot assay results suggest a ~10-fold decrease of 5hmC
levels in the new 5hmC spike-in control. Lux took the
impurity of the 5hmCTP mix into account automatically
through integrative analysis of all modifications and all
spike-in controls and updated the prior distributions in
light of the experimental data (Figure S12a in Additional
file 4); hence, the resulting experimental parameter esti-
mates were in the expected range (Table S7 in Additional
file 5). For instance, the posterior mean of oxeff varied
from 0.86 to 0.94 (Figure S12c in Additional file 4). Im-
portantly, none of the existing tools would be able to
correct these kinds of biases in the control data and/or
experimental parameters.
Next, we estimated the methylation status of all of the
cytosines with at least 10× coverage across all nine sam-
ples, that is, we analyzed 423 cytosines (64 are in a CpG
context; Table S7 in Additional file 5). We first repeated
the same correlation analysis between biological repli-
cates as for the embryonic stem cell data above. The cor-
relations for C and 5mC levels are again very high for
both Lux and MLML (data not shown). Interestingly, in
our T-cell data the 5hmC correlations (Figure S12d in
Additional file 4) are also notably higher compared with
the v6.5 data (Fig. 2d). Importantly, Lux achieves con-
sistently higher correlation values than MLML, although
the amount of increase is smaller than in the embryonic
stem cell data. For T-cell data, where oxidation efficiencies
are consistently good (Figure S12c in Additional file 4),
MLML is able to estimate consistent 5hmC levels be-
tween replicates, whereas for the embryonic stem cell
data, where oxidation efficiencies exhibit more variation
(Fig. 1e), 5hmC estimates from MLML are less consist-
ent. The Lux method, in turn, provides more consistent
5hmC estimates both for the embryonic stem cell and
T-cell data. Overall, our results reveal that Lux is not-
ably more consistent across biological replicates than
previous methods, thus suggesting that utilization of
experimental parameters improves the quantification
of cytosine modification levels.
We next detected differentially methylated cytosines in
a CpG context between any two cell types and identified
18, 29, and 17 differentially methylated cytosines (BF > 1)
from the comparisons of DP versus CD4 SP, DP versus
naïve CD4, and CD4 SP versus naïve CD4, respectively.
Altogether, 30 unique differentially methylated cytosines
were identified (Figure S12e in Additional file 4; Table S6
in Additional file 5). The rest of the cytosines were mostly
methylated in the three stages of development (average
5mC levels are 0.85, 0.84, and 0.77 in DP, CD4 SP, and
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naïve CD4 cells, respectively; Table S6 in Additional file
5). The average 5mC level of differentially methylated cy-
tosines decreases during the transitions from DP (0.71) to
CD4 SP (0.59) and further to naïve CD4 (0.32) (Figure
S12e in Additional file 4; Table S6 in Additional file 5).
Simultaneously, the average 5hmC level peaks in DP cells
(0.23, 0.08, and 0.02 in DP, CD4 SP, and naïve CD4 cells,
respectively), supporting the role of oxi-mC species in the
demethylation pathway (Figure S12e in Additional file 4;
Table S6 in Additional file 5). Collectively, we detected
gradual loss of 5mC during the transition from DP stage
to naïve CD4 stage within the three loci, which are im-
portant in mouse T-cell development. Interestingly, one of
the CpG dinucleotides that lost 5mC resides within a de-
tected canonical E-box motif occurrence in Il6ra (Fig. 5a).
Il6ra is not expressed in DP cells but it is highly expressed
in CD4/CD8 SP and naïve CD4/CD8 cells (Fig. 5b) [52–
54]. As many transcription factors binding the canonical
E-box motif are expressed during T-cell development [55],
and as DNA methylation is known to alter DNA conform-
ation and conformational changes in turn alter binding to
E-box motifs [56], it is plausible that this locus is occupied
by one or more readers of 5mC in DP cells and/or readers
of oxi-mC or unmodified cytosine in CD4 SP and naïve
CD4 cells.
Integrative analysis of genome-wide BS-seq, TAB-seq, and
fCAB-seq data
To further demonstrate the applicability of Lux in a
genome-wide setting, we analyzed recently published
BS-seq, TAB-seq, fCAB-seq data sets from two-cell em-
bryos [57]. Notably, the introduction of fCAB-seq allows
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the identification of 5fC, and consequently the cytosine-
specific probability vector θ = [p(C), p(5mC), p(5hmC),
p(5fC)] (Σθ = 1) is four-dimensional. First, we derive the
required statistical model by stating the propagated
probabilities of the possible outcomes of the BS-seq,
TAB-seq and fCAB-seq assays (Additional file 3; Figure
S13 in Additional file 4). Besides the aforementioned bi-
sulfite conversion (BSeff ) and inaccurate bisulfite conver-
sion (BS*eff ) efficiencies and sequencing error (seqerr),
here we considered labeling (labeff ), oxidation (oxeff ),
and protection (proeff ) efficiencies involved in TAB-seq
and fCAB-seq assays (Figure S13 in Additional file 4).
First, we confirmed using an in silico simulation ap-
proach that we can simultaneously identify experimental
parameters and methylation levels accurately from the
data (Figure S14a in Additional file 4). Indeed, our simu-
lations with different realistic methylation level/coverage
settings demonstrate Lux’s ability to produce consistent
(i.e., unbiased) methylation level estimates with notably
smaller variance than the frequency method estimator.
As expected, the frequency estimator produces often
negative methylation level estimates in the cases of low
5mC (hypo-5mC) and/or 5fC (hypo-5fC). This is an im-
portant point because cytosines with negative estimates
are typically ignored from downstream analysis.
Next, we estimated the four methylation modification
levels of the common (N = 12,350,189), maternal (N =
477,179) and paternal (N = 32,966) cytosines in a CpG
context with at least 10× coverage (Fig. 5c; Figure S14b
in Additional file 4; see "Materials and methods"). The
experimental values were set based on the values re-
ported in Wang et al. [57] (see "Materials and methods").
As reported previously, the 5hmC and 5fC levels are
modest in general (Fig. 5c; Figure S14b in Additional file 4);
for instance, 79 % and 46 % of the common cytosines
are lowly hydroxided (p(5hmC) ≤ 0.1) and/or formylated
(p(5fC) ≤ 0.1), respectively (Fig. 5c). However, for some
cytosines 5hmC and 5fC modification levels can reach
up to 0.3 and 0.6, respectively. Intriguingly, the distribu-
tions of the C and 5mC levels differ between the com-
mon and maternal cytosines (Fig. 5c; Figure S14b, top in
Additional file 4) as 10 % and 22 % of the common and
maternal cytosines are methylated (p(C) ≤ 0.1), respect-
ively. Lux automatically quantifies the amount of uncer-
tainty in estimated cytosine modification levels for each
cytosine via the full posterior distribution. As expected,
the standard deviations of the estimated posterior distri-
butions of methylation levels decrease when the sequen-
cing coverage increases (Figure S14c in Additional file
4). Notably, almost half of the considered cytosines had
negative 5mC or 5fC levels and would thus be ignored
(or truncated to zero) when the frequency method esti-
mator is used (Fig. 5d; see Figure S14d in Additional file
4 for the 5mC and 5hmC comparisons). As expected,
the similarity between the Lux and frequency method
estimates improves when cytosines with negative fre-
quency method estimates are ignored, but simultan-
eously almost half of the data is also ignored (Figure
S14e in Additional file 4), whereas Lux provides esti-
mates of methylation modification levels which are both
consistent (sum up to one) and take into account the
experiment-specific variation in biochemistry, i.e., non-
ideal experimental parameters. Finally, we visualized the
estimated C, 5mC, 5hmC, and 5fC levels across the
locus discussed in Wang et al. [57] (Fig. 5e). Note that
Lux can estimate all the four different modification
levels (instead of 5mC, 5fC and 5mC + 5hmC + 5fC) and
that the methylation levels of each cytosine sum up to
one.
Applicability of Lux to analyze other derivatives of
traditional bisulfite sequencing data
Above we described how Lux can analyze BS-seq, oxBS-
seq, TAB-seq and fCAB-seq data together with their
experimental parameters. Importantly, Lux is also applic-
able for the analysis of CAB-seq, redBS-seq and MAB-seq
data with minor changes. Another bisulfite-based tech-
nique, termed CAB-seq, was recently published for detect-
ing 5caC at nucleotide resolution [36], making it possible
to differentiate C, 5mC, 5hmC and 5caC. This requires an
integration of CAB-seq data with BS-seq and oxBS-seq/
TAB-seq data, which is easily implemented in Lux by de-
fining the generative model for the outcomes of a CAB-
seq experiment in terms of its related experimental pa-
rameters (Fig. 6a; Additional file 3) and combining that
with the likelihood functions of BS-seq and oxBS-seq/
TAB-seq data. An additional bisulfite-based technique,
redBS-seq, has been developed for detecting 5fC at indi-
vidual cytosine sites. Interestingly, Booth et al. [35] re-
ported that almost 30 % of the 5fC estimates obtained
using the frequency method estimator were negative,
which were then discarded from the subsequent ana-
lysis. This problem can only be resolved by using the in-
tegrative analysis of all cytosines as implemented in
Lux. Similar to CAB-seq, Lux can be straightforwardly
extended to redBS-seq and MAB-seq data (Fig. 6b, c;
Additional file 3). More generally, the hierarchical
framework implemented in Lux can be extended to
process data from various sequencing assays with se-
quential, error-prone experimental steps [33].
Conclusions
Here, we present a unified statistical framework, Lux, for
analyzing BS-seq and oxi-mC-seq data sets. Lux provides
several major improvements and extensions compared
with existing methods; for instance, it integrates BS-seq
and oxi-mC-seq measurements, models bisulfite conver-
sion and oxidation efficiencies, various chemical labeling
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and protection steps and sequencing errors, and analyzes
data from replicated experiments. No previous computa-
tional analysis methods exist which would have the above-
mentioned functionalities. Lux’s performance on detecting
experimental parameters, methylation levels, biological
variation and differential methylation was assessed exten-
sively on real and simulated data on various realistic
methylation levels ((C, 5mC, 5hmC): (0.8, 0.1, 0.1), (0.1,
0.8, 0.1), (0.6, 0.1, 0.3), (0.1, 0.6, 0.3), (0.7, 0.25, 0.05), (0.2,
0.7, 0.1); (C, 5mC, 5hmC, 5fC): (0.8, 0.1, 0.05, 0.05), (0.1,
0.8, 0.05, 0.05), (0.6, 0.1, 0.15, 0.15), and (0.1, 0.6, 0.15,
0.15) corresponding to different scenarios of strong hyper-
and hypomethylation, weak hyper- and hypomethylation,
as well as active demethylation (see also Figure S14b in
Additional file 4)). Through Bayesian inference, experi-
mental parameters and their associated uncertainties
propagate to the final estimates of methylation levels,
which makes it possible to compare samples with different
experimental parameters in a meaningful and statistically
justified manner. We have shown how the accuracy and
sensitivity of methylation estimates and the detection of
differential methylation are improved compared with pre-
vious methods when the non-ideal, sample-specific experi-
mental parameters and replicates are taken into account.
Our results support the previous guidelines for sequen-
cing depth requirements for discriminating completely
methylated cytosines from completely unmethylated cyto-
sines. Importantly, we further examined the detectability
of endogenous levels of 5hmC and demonstrated the im-
portance of biological replicates as well as experimental
parameters in detecting subtle changes in 5hmC or other
cytosine modifications.
Our detailed analysis of selected genomic loci revealed
TET2-dependent demethylation of individual cytosines
occurring at promoters and enhancers in mESCs. More-
over, we identified progressive loss of 5mC, leading to
production of 5fC, 5caC or unmodified cytosine (these
three cytosine species are experimentally indistinguishable
in our experimental conditions) in genes known to be
important for mouse T-cell development. The observed
effect of TET2 was only partial, suggesting that demethyl-
ation is controlled in parallel by multiple enzymes. As re-
ported previously, 5mC and 5hmC were only observed at
cytosines in a CpG context. Our analysis of biological rep-
licates illustrated the stochastic nature of demethylation.
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The observed stochasticity emphasizes the importance of
biological replicates, especially when the focus is on study-
ing differential methylation of individual cytosines. For
instance, the inclusion of the exon 5 of Ptprc during
lymphocyte activation is governed by methylation sta-
tus [10]. Low levels of DNA methylation on exon 5
allow CTCF binding and cause RNA polymerase II
pausing, thus resulting in exclusion of exon 5 [10]. Pre-
vious studies suggested that the interaction between
CTCF and DNA is affected by CpG methylation, even
at a single CpG site. Although antibody-based tech-
niques can be useful in detecting larger methylated
loci, their resolution is limited to the range of hundreds
of nucleotides. Furthermore, quantification and compari-
son of absolute proportions of different cytosine modifica-
tions from immunoprecipitation data are challenging,
whereas Lux automatically estimates absolute proportions
of Cs, 5mCs, and 5hmCs from BS-seq and oxBS-seq data
at single nucleotide resolution.
Deciphering the active demethylation pathway will re-
quire deconvolution of the effects of individual enzymes
to understand their orchestrated action. Moreover, it will
be intriguing to shed light on the interplay between tran-
scription factor binding and methylation using DNase
footprinting or ChIP-exo and BS-seq/oxi-mC-seq ap-
proaches, respectively. In addition, the interaction be-
tween DNA and other transcriptional factors can be
affected by DNA methylation at a single CpG site, such
as C/EBP [58]. It will be very interesting to examine how
oxidized 5mCs (5hmC, 5fC, and 5caC) affect the DNA
binding capability of transcriptional factors to regulate
gene expression. Although 5hmC, 5fC, and 5caC binding
proteins have been identified in mESCs and neural pro-
genitor cells, many transcriptional factors have their
own binding motif which might not be captured with
the approach of Spruijt et al. [59]. In combination with
the enrichment of certain transcription factors, single-
base resolution mapping of oxi-mC and Lux analysis
will provide insights into the effect of DNA modifica-
tions on DNA binding of transcriptional factors either
genome-wide or at the loci-specific scale. In addition,
understanding the role and importance of 5hmC and
other further oxidized cytosine modifications in tran-
scription will require temporal approaches for measur-
ing active transcription, such as nascent-seq, and the
capability of detecting temporal changes in methylation
levels at high resolution. In conclusion, all of the afore-
mentioned and many additional future research questions
will benefit greatly from Lux’s unique features of account-
ing for sample-specific variation in experimental parame-
ters when quantifying all cytosine modification levels from
replicated BS-seq and oxi-mC-seq data sets. All of Lux’s
functionality described above is implemented in the Lux
software, which has been made freely available.
Materials and methods
Embryonic stem cell culture and genomic DNA isolation
mESCs (v6.5) were cultured in Knockout DMEM (Invi-
trogen) with 20 % embryonic stem cell qualified fetal
bovine serum (Germini Bio-product), 2 mM L-glutam-
ine, 0.1 mM 2-mercaptoethanol, 0.1 mM nonessential
amino acids, 50 units/ml penicillin/streptomycin and
1000 U/ml ESGRO (LIF; Chemicon). Tet2 was stably
knocked down in v6.5 cells using electroporation with
pSUPER-puro-Tet2shRNA (320V, 250F) followed by
1.5 μg/ml puromycin selection for 7–10 days [60].
Genomic DNA was isolated with the DNeasy blood
and tissue kit (Qiagen) by following the manufacturer’s
instructions. Three independent cultures of wild-type
and Tet2kd samples were used.
Validation of Tet2 knockdown in mESCs
Tet2 knockdown efficiency was measured by quantitative
PCR (qPCR) and western blot [49]. For qPCR, total RNA
was isolated with an RNeasy kit (Qiagen, Chatsworth, CA,
USA) and cDNA was made using SuperScript III reverse
transcriptase (Invitrogen). qPCR was performed using
FastStart Universal SYBR Green Master mix (Roche,
Mannheim, Germany) on a StepOnePlus real-time PCR
system (Applied Biosystems, Foster City, CA, USA). Gene
expression was normalized to Gapdh. Primers used for
qPCR are listed below:
Tet1 forward: GAGCCTGTTCCTCGATGTGG
Tet1 reverse: CAACCCACCTGAGGCTGTT
Tet2 forward: AACCTGGCTACTGTCATTGCTCCA
Tet2 reverse: ATGTTCTGCTGGTCTCTGTGGGAA
Gapdh forward: GTGTTCCTACCCCCAATGTGT
Gapdh reverse: ATTGTCATACCAGGAAATGAGCTT
For western blot, nuclear proteins from parental and
Tet2 knock-down mESCs were extracted as previously
described [61]. Nuclear protein (30 μg) was loaded on
4–12 % Bis-Tris gels (Invitrogen) and transferred to
nitrocellulose membrane. Tet2 was detected using anti-
Tet2 (Abcam) antibodies. Loading control, beta-actin,
was detected using anti-beta actin from Abcam.
Mice
We used 4–6-week-old female C57BL/6 mice obtained
from Jackson labs for cell isolation. The mice were
housed in a pathogen-free animal facility in the La Jolla
Institute for Allergy and Immunology and were used
according to protocols approved by the Institutional
Animal Care and use Committee (IACUC).
Preparation of thymocyte subsets
Subsets of thymocytes were isolated by cell sorting as
previously described [54], after cell surface staining using
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CD4 (GK1.5), CD8 (53–6.7), CD3ε (145-2C11), and CD24
(M1/69) (all from Biolegend). DP cells were CD4+ CD8
int/hi; CD4 SP cells were CD4CD3 hi, CD24 int/lo. Per-
ipheral subsets were isolated after pooling spleen and
lymph nodes. T cells were enriched by negative isolation
using Dynabeads (Dynabeads untouched mouse T cells,
11413D, Invitrogen). After surface staining for CD4
(GK1.5), CD8 (53–6.7), CD62L (MEL-14), CD25 (PC61)
and CD44 (IM7), naïve CD4 + CD62LhiCD25-CD44lo
were obtained by sorting (BD FACS Aria). Three cell isola-
tions from independent mice were prepared for each of
the three thymocyte subsets.
Synthesis of cytosine-, 5mC- and 5hmC-containing control
oligonucleotides
Spike-in cytosine-, 5mC- and 5hmC-containing control
oligonucleotides were synthesized using unmethylated
lambda DNA (Promega) as template by PCR containing
dCTP, dmCTP (5mC) or dhmCTP (5hmC), respectively.
Regular dCTP was purchased from Promega, and
dmCTP and dhmCTP were purchased from Zymo Re-
search. PCR primers for control oligonucleotides are
listed below:
C control oligo forward:
ATTGTATGTATTGGTTTATTG
C control oligo reverse:
TTATCACATTCAAACATTAAT
5mC control oligo forward:
TAGATAGTAAATATAATGTGAGA
5mC control oligo reverse:
ATAAATCATCAACAAAACACAA
5hmC control oligo forward:
GTTTTTTTGAATAATAAATGTTA
5hmC control oligo reverse:
TTTATCACCTCTAAAATATATCA
PCR was performed using REDtaq DNA polymerase
(Sigma) by following the manufacturer’s instructions.
BS-seq and oxBS-seq
Purified genomic DNA with spike-in control oligonucle-
otides (1:50) was divided into two parts. One part was
directly treated with sodium bisulfite, while the other
was treated with KRuO4 to oxidize 5hmC to 5fC,
followed by bisulfite treatment. oxBS experiments were
performed by following the procedures described by
Booth et al. [32, 62]. Briefly, up to 1 μg ethanol-
precipitated genomic DNA was purified by Micro Bio-
Spin column (SSC buffer; Bio-Rad) and denatured in
24 μl 0.05M NaOH at 37 °C for 30 min. Denatured gen-
omic DNA was snap-cooled on ice for 5 min and
followed by adding 1 μl KRuO4 solution (15 mM in
0.05M NaOH). The reaction was performed on ice for
1 h with gentle flicks every 10–15 min. Next, reacted
genomic DNA was purified by Micro Bio-Spin column
(SSC buffer; Bio-Rad). Bisulfite reaction was performed
using the MethylCode bisulfite conversion kit (Invitro-
gen) by following the manufacturer’s Instructions. Loci-
specific primers against bisulfite-treated genomic DNA
were designed through the online MethPrimer software.
Regions of interest were amplified using oxBS- and BS-
treated genomic DNA as templates by using the Pyro-
Mark PCR kit (Qiagen) and further purified by AmpuXP
beads (Beckman coulter) in 96-well PCR plates. To pre-
pare libraries compatible with MiSeq, the concentration
of each amplicon was quantified by Nanodrop and nor-
malized to desired concentrations. In each condition,
normalized amplicons were pooled together and followed
by illumina library preparation using TruSeq DNA library
preparation kit (Illumina). Prepared libraries were
amplified for four cycles and purified by two rounds of
AmpuXP beads to remove the primer dimmers. The
quality of libraries was examined by Bioanalyzer (Agilent)
and then subjected to sequencing on MiSeq.
Preprocessing of BS-seq and oxBS-seq data
First the sequencing adapters were removed from the
reads when encountered. Bismark v0.7.12 [63] was used
to align the BS and oxBS reads against the mm9 refer-
ence genome and lambda phage DNA simultaneously.
The alignment was done using the paired-end Bowtie 2
[64] backend with the following parameters: -I 0 -X
2000 -N 0. The “bismark_methylation_extractor” script
distributed with the Bismark aligner was used to ex-
tract the number of unconverted and converted
read-outs for each cytosine with the following parameters:
–paired-end –CX –cutoff 10 –no_overlap –bedGraph
–counts. The cytosines having at least ten read-outs
across all six samples were taken into account. The
control cytosines located on the Watson strand were
used in the analysis.
Derivation of the statistical model
We first describe the statistical model to quantify C,
5mC and 5hmC from BS-seq and oxBS-seq data and
later extend Lux to other oxi-mC species and data types.
For a given cytosine, we use a Dirichlet random variable
of order three to model proportions of different cytosine
methylations θ = [p(C), p(5mC), p(5hmC)] (Σθ = 1) sim-
ultaneously and, for a given value of θ, we define BS-seq
and oxBS-seq likelihoods to have binomial distributions.
Thus, our model could be described as Dirichlet-
binomial2, where the binomial squared refers to the two
binomial distributions used in modeling BS-seq and
oxBS-seq data (Figure S2a in Additional file 4). Our
model can also be viewed as an extension of a previously
presented beta-binomial model, which is inadequate for
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simultaneous analysis of BS-seq and oxBS-seq data:
MOABS [43] uses the beta distribution to model separately
the probabilities p(C) + p(5mC or 5hmC) = 1 (BS-seq) and
p(C or 5hmC) + p(5mC) = 1 (oxBS-seq). Our generalization
makes it possible to analyze BS-seq and oxBS-seq data
(and later any number and combination of BS-seq and/or
oxi-mC-seq data sets) together and correctly deconvolve
the proportions of different cytosine modifications. This
procedure is explained in detail below.
To take into account the bisulfite conversion (BSeff ),
inaccurate bisulfite conversion (BS*eff ) and oxidation
(oxeff ) efficiencies as well as sequencing errors (seqerr),
we have to define their effects on the BS-seq and oxBS-
seq read-outs. Motivated by the chemical steps involved
in BS-seq and oxBS-seq experiments, we define the ef-
fects of BSeff, BS*eff, oxeff and seqerr on each of the cyto-
sine modifications (C, 5mC, 5hmC; Fig. 1b, c; Figure S1b
in Additional file 4) and derive the BS-seq- and oxBS-
seq-specific emission probabilities (propagated probabil-
ities; Figure S1c in Additional file 4). That is, we define
the probability of observing “C” in a BS-seq experiment
given that the nucleotide is unmethylated, pBS(“C”|C),
as:
pBS “C”jCð Þ ¼ 1−BSeffð Þ 1−seqerrð Þ þ BSeff seqerr;
and similarly for the other cases:
pBS “C”j5mCð Þ ¼ 1−BSeffð Þ 1−seqerrð Þ þ BSeff seqerr
pBS “C”j5hmCð Þ ¼ 1−BSeffð Þ 1−seqerrð Þ þ BSeff seqerr
poxBS “C”jCð Þ ¼ 1−BSeffð Þ 1−seqerrð Þ þ BSeff seqerr
poxBS “C”j5mCð Þ ¼ 1−BSeffð Þ 1−seqerrð Þ þ BSeff seqerr
poxBS “C”j5hmCð Þ ¼ oxeff ½ 1−BSeffð Þ 1−seqerrð Þ þ BSeff seqerr
þ 1−oxeffð Þ½ 1−BSeffð Þ 1−seqerrð Þ
þ BSeff seqerr:
We follow the standard practice and ignore “A” and
“G” read-outs as the reads containing these read-outs
are discarded during the mapping (their impact on the
estimates would be negligible), and, consequently, the
probability of the complementary events, i.e., reading
“T” instead of “C”, are one minus the aforementioned
probabilities. Parameters BSeff, BS*eff, oxeff and seqerr are
shared across cytosines but, importantly, specific for
each biological experiment.
In practice, BS-seq and oxBS-seq experiments are
carried out for a collection of cells, which comprise a
cytosine population. Consequently, the probability of
sequencing a “C” (for a given cytosine) in BS-seq ex-
periment is obtained by weighting the above emission
probabilities with the (unknown) cytosine proportions,
θ = [p(C), p(5hmC), p(5hmC)] (Figure S1d in Additional
file 4):
pBS “C”ð Þ ¼ p Cð ÞpBS “C”jCð Þ
þ p 5mCð ÞpBS “C”j5mCð Þ
þ p 5hmCð ÞpBS “C”j5hmCð Þ
poxBS “C”ð Þ ¼ p Cð ÞpoxBS “C”jCð Þ
þ p 5mCð ÞpoxBS “C”j5mCð Þ
þ p 5hmCð ÞpoxBS “C”j5hmCð Þ:
In other words, pBS(“C”) and poxBS(“C”) are the probabil-
ities of obtaining “C” in a single BS-seq and oxBS-seq
draw, respectively, from a cytosine population with pro-
portions p(C), p(5hmC) and p(5hmC). Thus, individual
“C” and “T” read-outs from BS-seq and oxBS-seq are Ber-
noulli distributed where the probabilities of observing “C”
are pBS(“C”) and poxBS(“C”), respectively. Consequently,
the counts of “C” read-outs, NBS,C and NoxBS,C, from
NBS BS-seq and NoxBS oxBS-seq draws, respectively, are
binomially distributed (Figure S2a in Additional file 4).
Because BS-seq and oxBS-seq data are conditionally
independent given model parameters, the likelihood of
data D = (DBS,DoxBS) for a single cytosine is the product
of the BS-seq and oxBS-seq likelihoods, p(DBS|θ,
BSeff,BS*eff,seqerr) and p(DoxBS|θ,BSeff,BS*eff,oxeff,seqerr).
Thus, under the binomial model the likelihood function
has the following form:
p DBS;DoxBSjθ;BSeff ;BSeff ; oxeff ; seqerrð Þ
¼ p DBSjθ;BSeff ;BSeff ; seqerrð Þ p DoxBSjθ;BSeff ;BSeff ; oxeff ; seqerrð Þ
¼ NBS
NBS;C
 
pBS }C}ð ÞNBS;C 1−pBS }C}ð Þð ÞNBS‐NBS;C
NoxBS
NoxBS;C
 
poxBS }C}ð ÞNoxBS;C 1−poxBS }C}ð Þð ÞNoxBS−NoxBS;C :
The complete likelihood is obtained by multiplying the
likelihoods of all cytosines in the studied regions and in
the control oligonucleotides.
Biological variation is modeled hierarchically (see also
Figure S2a in Additional file 4) by defining a condition-
specific mean μ for methylation proportions, and μ is
assigned a Dirichlet prior with hyperparameters α = (0.8,
0.8, 0.8), where α was selected to increase sensitivity of
the estimation even with low sequencing coverage. The
effect of α on estimation is studied systematically in Figure
S15a in Additional file 4. The sensitivity of the methyla-
tion estimation is greater and “bias” is smaller (i.e., fewer
data are needed to update the posterior), when the values
of the elements of α decrease. On the other hand, esti-
mates have larger variance when more a sensitive param-
eter is used. Thus, in the cases of relatively high coverage
we recommend the use of the default value of α.
Replicate specific methylation proportions θ are de-
fined to follow Dir(gμ + 1) distribution, where g repre-
sents biological variation around μ and was given a
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gamma prior with the shape parameter a = 2 and rate
parameter b = 2/6. The vector 1 is added in order to pre-
vent concentration of the probability mass in a few com-
ponents. The presented statistical model is described in
detail in Additional file 3.
Prior and hyperprior definitions
The knowledge on the purity of spike-in controls was
incorporated in the model through Dirichlet priors. The
parameters of the priors αC, α5mC and α5hmC were
defined so that they reflected expected and previously
reported purities of the dNTP, 5mC dNTP and 5hmC
dNTP mixes (Table S1 in Additional file 5) [28].
The probability model of the experimental parameters
BSeff, BS*eff, oxeff and seqerr is defined as a hierarchical
structure. Each experiment has its own set of parameter
values which are drawn from their corresponding prior
distributions. The shapes of the prior distributions are in
turn controlled by corresponding hyperpriors which are
defined by the user.
As the parameters BSeff, BS*eff, oxeff and seqerr repre-
sent probabilities, an intuitive way of eliciting the prior
knowledge would be by defining Beta distributions
through pseudo-counts or by specifying means and
standard deviations. However, as the mean and standard
deviation of each parameter depend on the experimen-
tal setup, we modeled them with hyperparameters. For
each of the parameters, the hyperparameter specifying
the mean models the expected value of that parameter
in each experiment, and the parameter specifying the
standard deviation models the spread of the values over
separate experiments.
When implementing the hierarchical probabilistic model
of the experimental parameters BSeff, BS*eff, oxeff and seqerr
and their respective hyperparameters, we decided not to
use the straightforward Beta parameterization but instead
use normal distributions and transformations of normal
distributions. This enables us to use noncentered parame-
terizations (NCPs) [65], which gives a significantly faster
sampler than one implemented with Beta distributions.
The parameters BSeff, BS*eff, oxeff and seqerr are modeled
with logistic-normal distributions [66]. The unconstrained
expected values of the corresponding distributions are
modeled with normal distributions and the correspond-
ing standard deviations with log-normal distributions
(see Figure S2a in Additional file 4; Table S1 in Additional
file 5). The values of the hyperhyperparameters were se-
lected so that they will produce distributions reflecting
our prior knowledge on BSeff, BS*eff, oxeff and seqerr; that
is, BSeff should be close to 1, oxeff should be around 0.95
and BS*eff and seqerr should be close to zero. The estima-
tion procedure is not sensitive to the selection of the
values of the hyperhyperparameters (Figure S15b in
Additional file 4). The default values should be applicable
for most of the cases. For a more detailed description,
see Additional file 3.
MCMC estimation of posterior distributions
After assigning priors and hyperpriors for the model pa-
rameters, the next step is to condition the model on data
and derive posterior distribution of the model parameters.
We use the Hamiltonian Monte Carlo (HMC) strategy
with the No-U-turn (NUTS) sampler [48] to sample the
posterior distributions. NUTS as implemented in Stan
v2.2.0 [67] was used in all the analyses with the following
settings: method = sample algorithm = hmc engine = nuts
max_depth = 8 stepsize = 0.02. The default numbers of
warm-up (1000) and sampling (1000) iterations were run.
The chains were initialized with values sampled from the
priors. The convergence of the MCMC chains was moni-
tored using the built-in Gelman and Rubin's convergence
diagnostic, the potential scale reduction factor [68].
Detection of differential methylation
Differential methylation between two conditions is quan-
tified by assessing the difference in the posterior distri-
butions of μ in conditions A and B. For this, we define
Δμ = μA − μB, where the difference is taken element-wise.
In addition, the null hypothesis H0 and alternative hy-
pothesis H1 are defined as Δμ = 0 and Δμ ≠ 0, respect-
ively. The BF is a measure of the evidence in the data D
in support of H1 over H0 BF = p(D|H1)/p(D|H0). The
calculation of the BF requires evaluation of the marginal
likelihoods of the data, which unfortunately do not have
closed-form solutions. We resort to the Savage-Dickey
density ratio for approximating the BF as BF ≃ p(Δμ =
0|H1)/p(Δμ = 0|D,H1). Next we will go through how we
calculated the numerator and denominator.
The value of the probability density function of the
difference of two independent Dirichlet random vari-
ables at the origin (0, 0, 0) can be solved analytically (see
Additional file 3). Thus, if μ1, μ2 ~ Dir((0.8, 0.8, 0.8)),
then p(Δμ = 0|H1) = pμ1-μ2((0, 0, 0)) ≃ 2.19712.
To calculate the value p(Δμ = 0|H1,D), we use two
MCMC chains containing posterior samples of μA and μB,
corresponding to the conditions A and B, and estimate
the empirical posterior distribution of the difference Δμ.
Here the estimation was done using a standard kernel
density estimation approach with the Gaussian kernel (the
routine scipy.stats.gaussian_kde in SciPy [69]). The density
is estimated based on all the pair-wise differences calcu-
lated between the samples of the two chains; in the case of
N samples per chain there are altogether N2 differences
used in the kernel density estimation. The bandwidth of
the kernel was selected to be one-fourth of the estimate
given by Scott’s rule [70]. The scaling factor of ¼ for the
bandwidth was included to improve the accuracy of the
kernel density estimates. The accuracy of the kernel
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density estimation was assessed in the following way: 1)
sample data from two known Dirichlet distributions; 2)
calculate the kernel density estimate for the difference be-
tween the two Dirichlet distributed variables using the
sampled data; and 3) compare the estimate with the true
value obtained using the analytical formula.
We systematically studied the effect of α on the detec-
tion of differential methylation (Figure S15c in Additional
file 4). Small α values result in more sensitive differential
detection estimation and larger BF values (Figure S15c in
Additional file 4). Note that the increase in the absolute
value of BF is mainly due to the denominator term, which
is calculated based on the prior in the Savage-Dickey es-
timator. In the case of the Jeffreys non-informative prior
(α = (0.5,0.5,0.5); which would produce most sensitive
methylation estimates), the Savage-Dickey density ratio
is not applicable because the denominator calculated
based on the prior is always 0.
Detection of differential methylation at the locus level
At the locus level, Lux accounts for two types of variability:
variability between individual cytosines within a locus, and
variability in individual cytosine methylation levels between
biological replicates. This is achieved by introducing an
additional level to the Lux model (Figure S11 in Additional
file 4). That is, variation in methylation across a locus is
modeled hierarchically by first defining a condition-specific
mean μ for methylation proportions in a locus, and μ is
assigned a Dirichlet prior with hyperparameters α = (0.8,
0.8, 0.8), where α was selected to increase sensitivity of the
estimation even with low sequencing coverage. Methyla-
tion proportions ν over individual cytosines within a locus
are defined to follow Dir(gμ + 1) distribution, where g rep-
resents biological variation around μ and was given a
gamma prior with the shape parameter a = 2 and rate par-
ameter b = 2/6. The vector 1 is added in order to prevent
concentration of the probability mass in a few components.
Finally, replicate-specific methylation proportions θ are de-
fined to follow Dir(fν +1) distribution, where f represents
variation around ν and was given a gamma prior with the
shape parameter a = 2 and rate parameter b = 2/6. Differen-
tial methylation between two conditions is quantified as
described above by assessing the difference in the posterior
distributions of μ in conditions A and B.
To scan our loci, we used a scanning window ap-
proach with window-length 100 bp and step-size 50 bp.
In our analysis we only considered those cytosines which
were in a CpG context. Moreover, we ignored those win-
dows which had less than three cytosines, as those are
better quantified using cytosine-level analysis.
Defining differentially and similarly methylated cytosines
To compare Lux, MOABS, and FET in detecting differ-
ential methylation we have to define sets of differentially
and similarly methylated cytosines. This was done by de-
tecting ten top scoring loci and four low scoring loci
showing differential 5mC and/or 5hmC levels based on
independent CMS-IP and MeDIP measurements [49].
The detection of loci with differential 5mC and 5hmC
was done using the MEDIPS tool [71] with 300 bp win-
dows (p value < 1e-4). All the covered cytosines in a
CpG context (N = 384) were divided into sets of differen-
tially (N = 252) and similarly (N = 132) methylated cyto-
sines based on the aforementioned loci-level information.
The same procedure was carried out while defining differ-
entially and similarly methylated windows in Figure S11b
in Additional file 4.
DNA modification-sensitive assays like MeDIP and
CMS-IP are known to have a CpG density bias. Espe-
cially regions with low CpG densities will result in only
moderate signals, even when fully methylated. Various
methods have been proposed to transform MeDIP-seq-
derived count data into beta-like absolute methylation
values by correcting for CpG densities [71–74]. How-
ever, any experiment-independent bias, like local CpG
density, affects each sample the same way. Therefore, no
normalization of CpG density or other experiment-
independent factors needs to be performed when differ-
ential methylation at a fixed region and between samples
is calculated. For validation of our method, we have fo-
cused on genomic regions identified as differentially
methylated (MeDIP) and differentially hydroxymethy-
lated (CMS-IP) comparing conditions and the selected
regions all have balanced and elevated CpG densities.
Although MeDIP and CMS-IP do not provide informa-
tion on the single nucleotide level, they have been used
to detect differential 5mC and 5hmC successfully. More-
over, it has also been reported that in many cases the
methylation levels of several nearby CpG sites are highly
correlated. Finally, MeDIP and CMS-IP are independent
techniques from BS-seq and oxBS-seq and, thus, provide
orthogonal information.
Using MOABS
To compare Lux with MOABS in detecting differential
methylation we first downloaded the MOABS (v.1.2.7)
binaries from https://code.google.com/p/moabs/. We
generated necessary input files (in the BED format) con-
taining information about methylation calls as described
in the MOABS user guide (v.1.2.2). Then, we carried out
differential methylation analysis of individual cytosines
between two conditions with (“mcomp –doDmrScan =
0 -r c1_r1.bed,c1_r2.bed,c1_r3.bed -r c2_r1.bed,c2_r2.-
bed,c3_r3.bed -m c1.bed c2.bed -c c1_vs_v2.txt”) or
without replicates (“mcomp –doDmrScan 0 -r c1.bed -r
c2.bed -c c1_vs_c2.txt”) using the mcomp module as de-
scribed in the user guide. To carry out differential
methylation of windows, we used mcomp (“mcomp -r
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c1_r1.bed,c1_r2.bed,c1_r3.bed -r c2_r1.bed,c2_r2.-
bed,c3_r3.bed -m c1.bed c2.bed -c c1_vs_v2.txt” and
“mcomp -c c1_vs_v2.txt -f window.bed”) and the obtained
p values were used. Based on the user guide, mcomp
does not support simultaneous analysis of BS-seq and
oxBS-seq data, and thus we analyzed BS-seq and oxBS-
seq data separately.
Binomial test with conversion efficiency
We used the binomial test with the conversion efficien-
cies (BSEff = 0.99) as described in the supplement of [32]
to quantify the presence of 5mC and 5hmC for each
CpG. Since [32] does not provide a way to handle repli-
cates, we combined the replicate-specific p values using
Fisher’s method. We used this strategy to analyze both
wild-type and knockout conditions separately. The ob-
tained p values therefore provide a proxy for the amount
of 5mC and 5hmC; low p values correspond to high
amounts of cytosine modifications. Using a p value
threshold we can decide the presence of 5mC and/or
5hmC in both conditions and call a difference in methy-
lation modification levels, which we defined by using
the minimum of the two p values. Finally, by sliding
the p value threshold from 0 to 1 we can then generate
the ROC graph and the AUC score as illustrated in Figure
S8d in Additional file 4.
Simulation of data
The counts of unconverted read-outs out of N read-outs
from BS-seq and oxBS-seq experiments are assumed to be
binomially distributed random variables with the derived
emission probabilities. The experimental parameters and
methylation levels are varied as indicated.
Downsampling was done by sampling data from bino-
mial distributions defined by the parameters estimated
from the complete data. That is, for a given cytosine and
BS-seq experiment we calculated the fraction of uncon-
verted read-outs, NBS,C/NBS. This value was used as the
success probability parameter, i.e., the probability of ob-
serving “C”. Using the defined binomial distribution, we
sampled a number of “C” read-outs out of N read-outs.
The same procedure was used for oxBS-seq but in that
case we calculated the fractions NoxBS,C/NoxBS.
Kernel density estimation in the open two-dimensional
simplex
A kernel density estimator was applied to data prior to
ternary plotting. To deal with compositional data correctly
we utilized a published method based on the use of the
isometric log-ratio normal kernel (iln) [75].
Comparison with glucMC-qPCR data
The raw BS-seq and oxBS-seq data sets were down-
loaded from the European Molecular Biology Laboratory-
European Bioinformatics Institute ArrayExpress Archive
(E-MTAB-1042). Bismark v0.7.12 [63] was used to align
the BS and oxBS reads against the mm9 reference gen-
ome. The alignment was done using the single-end Bowtie
2 [64] backend with the following parameters: -N 1 –L 20.
The “bismark_methylation_extractor” script distributed
with the Bismark aligner was used to extract the num-
ber of unconverted and converted read-outs for each
cytosine with the following parameters: –cutoff 5 –bed-
Graph –counts. The PCR primers given in [32] were
aligned against the mm9 reference genome and the loca-
tions of the CCGG sites within the loci were extracted.
The methylation levels of the second cytosine within the
CCGG sites were estimated using Lux (α = (0.8, 0.8, 0.8)).
The Booth et al. estimates and glucMS-qPCR measure-
ments were taken from [32].
Integrative analysis of BS-seq, TAB-seq, and fCAB-seq
data
First, we derived the statistical model for the simultan-
eous and integrative analysis of BS-seq, TAB-seq, and
fCAB-seq data. The derivation of BS-seq/TAB-seq/fCAB-
seq model followed the same principle as the aforemen-
tioned derivation of the BS-seq/oxBS-seq model. Briefly,
for a given cytosine, we used a Dirichlet random variable
of order four to model proportions of different cytosine
methylations θ = [p(C), p(5mC), p(5hmC), p(5fC)] (Σθ = 1)
simultaneously. Similarly as in the derivation of the BS-
seq/oxBS-seq model, we define the effects of BSeff, BS*eff,
labeff, oxeff, proeff and seqerr on each of the cytosine modi-
fication (C, 5mC, 5hmC, 5fC) and the BS-seq/TAB-seq/
fCAB-seq read-outs (Additional file 3; Figure S13 in
Additional file 4). Then we derive the BS-seq-, TAB-
seq-, and fCAB-seq-specific emission probabilities
(propagated probabilities; Additional file 3). Finally, for
given a value of θ, we define BS-seq, TAB-seq, and
fCAB-seq likelihoods to have binomial distributions as
in the BS-seq/oxBS-seq model. Consequently, we can
define the complete likelihood function as in the case of
the BS-seq/oxBS-seq model.
The preprocessed BS-seq, TAB-seq, and fCAB-seq data
sets (GSM1386021, GSM1386028, and GSM1386029)
were downloaded from the Gene Expression Omnibus
(GEO) database. We limited our analysis to the cytosines
(common, maternal, and paternal) on the positive strand
because no preprocessed BS-seq data were available
for the cytosines on the negative strand. Moreover,
we only considered the cytosines (N = 12,860,334)
with ≥10× coverage in all three experiments (BS-seq,
TAB-seq, and fCAB-seq).
Because no controls were available for all the experimen-
tal parameters, we set the values of the experimental pa-
rameters to the values reported in the original study [57],
i.e., BSeff = 0.99, labeff = 0.95, oxeff = 0.95, and proeff = 0.8.
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Moreover, we assumed that BS*eff = 0.001 and seqerr =
0.001. Finally, given the relatively low sequencing coverage
in the genome-wide data, we assigned the Jeffreys prior
for μ, i.e., μ ~Dir(α), where α = (0.5, 0.5, 0.5, 0.5).
Next, as with the BS-seq/oxBS-seq model, we used the
HMC sampling scheme to estimate the posterior distri-
butions of μ and θ for each of the considered cytosines
given the read count data and the values of the experi-
mental parameters.
Integrative analysis of other derivatives of traditional
bisulfite sequencing data
Besides BS-seq, oxBS-seq, TAB-seq and fCAB-seq, Lux
can be easily extended to analyze and quantify other
oxi-mC-seq data. The main experimental steps and the
corresponding parameters for CAB-seq, redBS-seq and
MAB-seq are shown in Fig. 6. Details of the propagated
probabilities, which are needed to compute the likelihood
are shown in Additional file 3.
Availability of software implementation
A platform-independent implementation of Lux is released
under MIT license at https://github.com/tare/Lux/ and as
Additional files 1 and 2. We recommend to get the latest
version from the GitHub repository.
Availability of experimental data
The data sets supporting the results of this article are
available in the GEO repository under accession number
GSE68576.
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